8-K: Avidity Secures Lonza Manufacturing, Reports Strong Q2 Progress

Avidity Biosciences entered a significant manufacturing agreement with Lonza and reported its second-quarter 2025 financial results, highlighting clinical progress and a strong cash position.

Summary

• Avidity Biosciences entered into a Manufacturing Services Agreement with Lonza LTD and Lonza Sales LTD on August 1, 2025, for the manufacture of drug substance and drug product for future commercial use.
• The company committed to purchase a minimum of approximately $620.0 million in Product from Lonza during the period from 2026 to 2028, subject to foreign currency changes and net of nonrefundable reservation fees.
• The Manufacturing Services Agreement has a seven-year term, ending on August 1, 2032.
• Avidity reported cash, cash equivalents, and marketable securities totaling approximately $1.2 billion as of June 30, 2025.
• Following the end of Q2 2025, the company received net proceeds of $185.5 million from the sale of stock through its at-the-market offering program.
• Collaboration revenues for the second quarter of 2025 were $3.8 million, an increase from $2.0 million for the same period in 2024.
• Research and development expenses for Q2 2025 increased to $138.1 million, compared to $63.9 million for Q2 2024, primarily due to the advancement of clinical programs.
• General and administrative expenses for Q2 2025 were $36.9 million, up from $20.7 million for Q2 2024, driven by higher personnel and commercial infrastructure costs.
• The net loss for Q2 2025 was $(157.3) million, compared to a net loss of $(70.8) million for Q2 2024.
• Net loss per share for Q2 2025 was $(1.21), compared to $(0.65) for Q2 2024.
• Delpacibart zotadirsen (del-zota) for Duchenne muscular dystrophy with mutations amenable to exon 44 skipping (DMD44) received U.S. FDA Breakthrough Therapy designation in July 2025.
• Enrollment was completed in July 2025 for the Phase 3 HARBOR trial of delpacibart etedesiran (del-desiran) for myotonic dystrophy type 1 (DM1).
• Delpacibart braxlosiran (del-brax) for facioscapulohumeral muscular dystrophy (FSHD) achieved alignment with the FDA on accelerated and full approval pathways and reported positive topline Phase 1/2 FORTITUDE data.
• A global, confirmatory FORTITUDE-3 study for del-brax was initiated, intended to support global approval strategy.

Sentiment

Score: 8

Explanation: The filing indicates strong clinical progress across multiple late-stage programs, significant regulatory milestones (Breakthrough Therapy, FDA alignment), and a robust cash position extending the runway to mid-2027. While expenses and net loss increased, this is expected for a company advancing towards commercialization. The long-term manufacturing agreement secures future supply, de-risking commercialization. This combination of factors suggests a very positive outlook.

Positives

• Secured a long-term Manufacturing Services Agreement with Lonza for commercial supply of drug substance and product, ensuring future manufacturing capabilities.
• FDA granted Breakthrough Therapy designation to del-zota (DMD44), which may expedite its development and regulatory review process.
• Completed enrollment in the Phase 3 HARBOR trial for del-desiran (DM1), a critical step towards potential market approval.
• Achieved alignment with the FDA on both accelerated and full approval pathways for del-brax (FSHD).
• Reported positive topline Phase 1/2 FORTITUDE data for del-brax, demonstrating consistent improvement in functional and quality of life measures, and significant reductions in relevant biomarkers.
• Initiated the global, confirmatory Phase 3 FORTITUDE-3 study for del-brax, supporting a comprehensive global approval strategy.
• Maintained a strong financial position with approximately $1.2 billion in cash, cash equivalents, and marketable securities as of June 30, 2025.
• Extended cash runway to mid-2027, enabling global commercial launch readiness for potential products.
• Increased collaboration revenues to $3.8 million in Q2 2025 from $2.0 million in Q2 2024.

Negatives

• Research and development expenses significantly increased to $138.1 million in Q2 2025 from $63.9 million in Q2 2024, reflecting higher costs for advancing clinical programs.
• General and administrative expenses rose substantially to $36.9 million in Q2 2025 from $20.7 million in Q2 2024, driven by increased personnel and commercial infrastructure costs.
• Net loss widened to $(157.3) million in Q2 2025 from $(70.8) million in Q2 2024.
• Net loss per share increased to $(1.21) in Q2 2025 from $(0.65) in Q2 2024.
• Committed to a minimum purchase of approximately $620.0 million in Product from Lonza over 2026-2028, representing a substantial future financial obligation.

Risks

• Actual results may differ from forward-looking statements due to inherent business risks and uncertainties.
• Clinical trial data and results may not be indicative of final results, may not support BLA submissions or accelerated approvals, or may not be satisfactory to the FDA and other regulators.
• New analyses of existing data and results may produce different conclusions than initially established.
• Even if approved, the company may not be able to execute successful product launches.
• Efforts to build a global commercial organization may be unsuccessful.
• Unexpected adverse side effects or inadequate efficacy of product candidates could delay or limit their development, regulatory approval, and/or commercialization.
• Later developments with the FDA and other global regulators could be inconsistent with feedback received to date.
• The Antibody Oligonucleotide Conjugates (AOC) platform is unproven and may not produce any products of commercial value.
• Potential delays in the commencement, enrollment, data readouts, and completion of clinical trials.
• Dependence on third parties for clinical testing and product manufacturing.
• Legislative, judicial, and regulatory developments in the United States and foreign countries could impact operations.
• Available capital resources could be exhausted sooner than currently expected.

Future Outlook

Avidity plans for three potential Biologics License Application (BLA) submissions over a 12-month period, with the first potential commercial launch in the U.S. in 2026. The company expects its cash runway to extend to mid-2027, enabling global commercial launch readiness. Key data readouts and marketing application submissions are anticipated for its lead programs in FSHD, DMD44, and DM1 through 2026, including topline data from the HARBOR study and FORTITUDE biomarker cohort in Q2 2026, and planned BLA submissions for del-zota by year-end 2025 and del-brax in H2 2026.

Management Comments

• "Avidity continues to deliver on its leadership in RNA therapeutics as we prepare for three potential BLA submissions in a 12-month period with strong clinical data, regulatory progress, and operational execution." Sarah Boyce, President and CEO.
• "Our programs in FSHD, DMD44 and DM1 each made meaningful advances during the second quarter of 2025, and we are encouraged by the consistent and reproducible data across these late-stage neuromuscular programs." Sarah Boyce, President and CEO.
• "We are keenly aware of the challenges facing patients and families living with these conditions and are preparing for potential commercialization with great thoughtfulness and urgency." Sarah Boyce, President and CEO.
• "Avidity continues to operate from a position of financial strength." Mike MacLean, CFO.
• "Aviditys recent topline data for del-brax continues to demonstrate the consistency of the platform." Mike MacLean, CFO.
• "As we move quickly toward potentially three successive launches starting in 2026, we continue to make meaningful progress in building our global infrastructure." Mike MacLean, CFO.

Industry Context

The biopharmaceutical industry is highly competitive, particularly in the development of RNA therapeutics and treatments for rare diseases. Avidity's focus on Antibody Oligonucleotide Conjugates (AOCs) represents an innovative approach to targeted RNA delivery, aiming to address diseases previously considered untreatable. The significant progress in its late-stage neuromuscular programs (DMD, DM1, FSHD), coupled with regulatory milestones like FDA Breakthrough Therapy designation for del-zota, positions Avidity as a notable contender in these high-unmet-need therapeutic areas. The long-term manufacturing agreement with Lonza is a strategic move to secure commercial supply, a critical factor for biotechs transitioning from clinical development to market launch.

Comparison to Industry Standards

• NA

Stakeholder Impact

• **Shareholders:** Potential for significant value creation if clinical programs succeed and products are commercialized, but also increased operational costs leading to wider net losses in the short term. The at-the-market offering diluted existing shares but strengthened the cash position, supporting future growth.
• **Patients and Families:** Significant positive impact due to accelerated development and potential availability of new treatments for Duchenne muscular dystrophy, myotonic dystrophy type 1, and facioscapulohumeral muscular dystrophy, conditions with high unmet medical needs.
• **Employees:** Growth in operations and commercial infrastructure suggests potential for job creation and stability as the company expands.
• **Suppliers (Lonza):** Secured a substantial, long-term manufacturing contract, ensuring a steady revenue stream and strategic partnership.

Next Steps

• Planned BLA submission for del-zota (DMD44) at year-end 2025.
• Present topline and functional data from the EXPLORE44-OLE trial (del-zota) in Q4 2025.
• Share updates from the MARINA-OLE trial, including long-term 4 mg/kg efficacy and safety data (del-desiran), in Q4 2025.
• Expected publication of data analyses from the completed Phase 1/2 MARINA trial (del-desiran) in 2025.
• Topline data readout from the HARBOR study (del-desiran) anticipated in Q2 2026.
• Marketing application submissions for del-desiran (U.S., E.U., Japan) anticipated to start in H2 2026.
• Topline data from FORTITUDE biomarker cohort (del-brax) anticipated in Q2 2026.
• Planned BLA submission for accelerated approval for del-brax in H2 2026.
• First potential commercial launch in the U.S. in 2026.

Key Dates

Recommendation

The company is demonstrating strong execution on its clinical pipeline with multiple programs advancing to late-stage development and achieving significant regulatory milestones, including a Breakthrough Therapy designation and FDA alignment on approval pathways. The securing of a long-term manufacturing agreement with Lonza de-risks future commercial supply. Despite increased operating expenses and net losses, these are expected for a biotech company in this growth phase, and the robust cash position, extended by a recent capital raise, provides a runway to mid-2027, supporting anticipated commercial launches starting in 2026. This combination of clinical progress, regulatory validation, and financial stability makes it an attractive investment for long-term growth.

Keywords

Avidity Biosciences, RNA therapeutics, Antibody Oligonucleotide Conjugates, AOCs, Duchenne muscular dystrophy, DMD44, myotonic dystrophy type 1, DM1, facioscapulohumeral muscular dystrophy, FSHD, del-zota, del-desiran, del-brax, Lonza, manufacturing agreement, biopharmaceutical, clinical trials, FDA Breakthrough Therapy, Q2 2025 earnings, biotech, rare muscle diseases